BridgeMD
New treatment option for Squamous Cell Carcinoma
Official title Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
ClinicalTrials.gov ID: NCT05108090
What this study is testing
- What it's testing
- The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients ≥ 18 years old at the time of informed consent
- Ability to provide written informed consent and HIPAA authorization
- Primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on AJCC staging
- Clinically and radiographically regional node-negative (no evidence of regional lymph node metastasis or distant metastasis)
- Able to undergo general anesthesia for sentinel lymph node biopsy
You likely can't join if
- Clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases
- Known biopsy proven synchronous primary cutaneous squamous cell carcinoma
- Pregnant patients
- Patients unable to undergo general anesthesia
- Patient unable to receive contrasted imaging studies
- Patient unable to receive and/or allergic to 99m-Technetium sulfur colloid
See the full eligibility criteria
- Patients ≥ 18 years old at the time of informed consent
- Ability to provide written informed consent and HIPAA authorization
- Primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on AJCC staging
- Clinically and radiographically regional node-negative (no evidence of regional lymph node metastasis or distant metastasis)
- Able to undergo general anesthesia for sentinel lymph node biopsy
- Able to undergo CT scan with contrast or MRI with contrast
- Undergo surgical resection (Moh's or micrographic resection or standard excision with sentinel lymph node biopsy) within 8 weeks of imaging
- Clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases
- Known biopsy proven synchronous primary cutaneous squamous cell carcinoma
- Pregnant patients
- Patients unable to undergo general anesthesia
- Patient unable to receive contrasted imaging studies
- Patient unable to receive and/or allergic to 99m-Technetium sulfur colloid
The study team makes the final eligibility decision.
Where it's taking place
- Indianapolis, Indiana, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Indianapolis, Indiana, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.